Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions

Postoperative Incidental Small Cell Lung CancerToripalimab Adjuvant Therapy Evaluation

Interventions

DRUG

Etoposide

Specified dose on specified days.

DRUG

Platinum

Specified dose on specified days.

DRUG

Toripalimab

Specified dose on specified days.

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER